ETS1 and neoplasm: The combinatorial treatment of OT-I cells deficient for Ets1 with anti-PD-L1 enhanced antitumour effects compared with control groups in B16-OVA and E.G7-OVA tumours (Fig. 3j and Extended Data Fig. 5i), which suggested that targeting Ets1 in CD8+ T cells enhances the ICB response.